

=> d his

(FILE 'HOME' ENTERED AT 19:12:36 ON 19 SEP 2002)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 19:12:45 ON 19 SEP 2002

L1 23794 S CARDIOMYOCYTE
L2 276418 S CORONARY(W) (ARTERY OR SINUS)
L3 6372 S AAV OR ADENO-ASSOCIATED(3A) VECTOR
L4 5 S L1 AND L2 AND L3
L5 3 DUP REM L4 (2 DUPLICATES REMOVED)

=> d bib ab 1-3 15

L5 ANSWER 1 OF 3 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2002:263208 BIOSIS
DN PREV200200263208
TI Localized delivery of **adeno-associated virus**
vector expressing human extracellular superoxide dismutase gene
confers long term protection against ischemia-reperfusion injury to the
rat heart.
AU Agrawal, Reitu S. (1); Muangman, Suphichaya; Melo, Luis G.; Layne,
Matthew
D.; Lopez-Ilasaca, Marco; Perrella, Mark A.; Lee, Richard T.; Zhang,
Lunan; Dzau, Victor J.
CS (1) Brigham and Women's Hosp, Boston, MA USA
SO Circulation, (October 23, 2001) Vol. 104, No. 17 Supplement, pp. II.36.
<http://circ.ahajournals.org/>. print.
Meeting Info.: Scientific Sessions 2001 of the American Heart Association
Anaheim, California, USA November 11-14, 2001
ISSN: 0009-7322.
DT Conference
LA English

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2002 ACS
AN 2000:456818 CAPLUS
DN 133:53712
TI Efficient and stable in vivo gene transfer to **cardiomyocytes**
using recombinant **adeno-associated virus**
vectors
IN Leiden, Jeffrey M.; Svensson, Eric
PA Arch Development Corp., USA
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000038518	A1	20000706	WO 1999-US31093	19991228
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

EP 1139751 A1 20011010 EP 1999-967703 19991228
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 PRAI US 1998-113923P P 19981228
 WO 1999-US31093 W 19991228
 AB Recombinant **adeno-assocd.** virus (rAAV) **vectors**
 are used to transduce **cardiomyocytes** in vivo by infusing the
 rAAV into a **coronary artery** or **coronary**
sinus. RAAV infection is not assocd. with detectable myocardial
 inflammation or myocyte necrosis. Thus, rAAV is a useful vector for the
 stable expression of therapeutic genes in the myocardium and can be used
 to deliver genes for inducing angiogenesis, inhibiting angiogenesis,
 stimulating cell proliferation, inhibiting cell proliferation and/or
 treating or ameliorating other cardiovascular conditions.
 RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 MEDLINE DUPLICATE 1
 AN 1999110721 MEDLINE
 DN 99110721 PubMed ID: 9892583
 TI Efficient and stable transduction of **cardiomyocytes** after
 intramyocardial injection or intracoronary perfusion with recombinant
adeno-associated virus vectors.
 AU Svensson E C; Marshall D J; Woodard K; Lin H; Jiang F; Chu L; Leiden J M
 CS Departments of Medicine and Pathology, University of Chicago, Chicago, IL
 60637, USA.
 NC AR-42885 (NIAMS)
 DK-48987 (NIDDK)
 HL-54592 (NHLBI)
 SO CIRCULATION, (1999 Jan 19) 99 (2) 201-5.
 Journal code: 0147763. ISSN: 1524-4539.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Abridged Index Medicus Journals; Priority Journals
 EM 199902
 ED Entered STN: 19990311
 Last Updated on STN: 20010521
 Entered Medline: 19990223
 AB BACKGROUND: The delivery of recombinant genes to **cardiomyocytes**
 holds promise for the treatment of a variety of cardiovascular diseases.
 Previous gene transfer approaches that used direct injection of plasmid
 DNA or replication-defective adenovirus vectors have been limited by low
 transduction frequencies and transient transgene expression due to immune
 responses, respectively. In this report, we have tested the feasibility
 of using intramyocardial injection or intracoronary infusions of recombinant
adeno-associated virus (rAAV) vectors to
 program transgene expression in murine **cardiomyocytes** in vivo.
 METHODS AND RESULTS: We constructed an rAAV containing the LacZ gene
 under the transcriptional control of the cytomegalovirus (CMV) promoter
 (AAVCMV-LacZ). We then injected 1x10⁸ infectious units (IU) of this
 virus into the left ventricular myocardium of adult CD-1 mice. Control
 hearts were injected with the AdCMV-LacZ adenovirus vector. Hearts
 harvested 2, 4, and 8 weeks after AAVCMV-LacZ injection demonstrated
 stable beta-galactosidase (beta-gal) expression in large numbers of
cardiomyocytes without evidence of myocardial inflammation or
 myocyte necrosis. In contrast, the AdCMV-LacZ-injected hearts displayed
 transient beta-gal expression, which was undetectable by 4 weeks after

injection. Explanted C57BL/6 mouse hearts were also perfused via the **coronary arteries** with 1.5×10^9 IU of AAVCMV-LacZ and assayed 2, 4, and 8 weeks later for beta-gal expression. beta-Gal expression was detected in <1% of **cardiomyocytes** at 2 weeks after perfusion but was detected in up to 50% of **cardiomyocytes** 4 to 8 weeks after perfusion. CONCLUSIONS: Direct intramyocardial injection or **coronary artery** perfusion with rAAV vectors can be used to program stable transgene expression in **cardiomyocytes** in vivo. rAAV appears to represent a useful vector for the delivery of therapeutic genes to the myocardium.

=>

WEST**Freeform Search****Database:**

US Patents Full-Text Database
 US Pre-Grant Publication Full-Text Database
 JPO Abstracts Database
 EPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Term:

14 and infusi\$

Display: **Documents in Display Format:** **Starting with Number** **Generate:** ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

Search History**DATE:** Thursday, September 19, 2002 [Printable Copy](#) [Create Case](#)**Set Name Query**
side by side**Hit Count Set Name**
result set*DB=USPT,PGPB; PLUR=YES; OP=AND*

<u>L5</u>	14 and infusi\$	30	<u>L5</u>
<u>L4</u>	11 and 12 and 13	38	<u>L4</u>
<u>L3</u>	aav or adeno-associated near3 vector	2182	<u>L3</u>
<u>L2</u>	coronary adj (artery or sinus)	12488	<u>L2</u>
<u>L1</u>	cardiomyocyte	530	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 20 of 30 returned.**

-
- ☐ 1. [20020132753](#). 17 Jan 01. 19 Sep 02. Nucleic acids, proteins, and antibodies. Rosen, Craig A., et al. 514/1; 435/320.1 435/325 435/6 435/69.1 536/23.1 A61K031/00 C12Q001/68 C07H021/02.
-
- ☐ 2. [20020120103](#). 27 Jul 01. 29 Aug 02. 17 human secreted proteins. Rosen, Craig A., et al. 530/350; 435/320.1 435/325 435/6 435/69.1 530/388.1 536/23.5 C12Q001/68 C07K014/435 C07H021/04 A61K038/17 C12P021/02 C12N005/06.
-
- ☐ 3. [20020098541](#). 17 Apr 01. 25 Jul 02. TNFR related gene 12. Ni, Jian, et al. 435/69.1; 435/320.1 435/325 435/6 530/350 536/23.5 C12Q001/68 C07H021/04 C12P021/02 C12N005/06 C07K014/705.
-
- ☐ 4. [20020090673](#). 17 Jan 01. 11 Jul 02. Nucleic acids, proteins, and antibodies. Rosen, Craig A., et al. 435/69.1; 435/320.1 435/325 435/6 536/23.1 C12Q001/68 C07H021/04 C12P021/02 C12N005/06 C12N015/74.
-
- ☐ 5. [20020086821](#). 17 Jan 01. 04 Jul 02. Nucleic acids, proteins, and antibodies. Rosen, Craig A., et al. 514/12; 435/183 435/320.1 435/325 435/69.1 536/23.1 A61K038/17 C07H021/04 C12N009/00 C12P021/02 C12N005/06.
-
- ☐ 6. [20020077287](#). 11 May 01. 20 Jun 02. 28 human secreted proteins. Ruben, Steven M., et al. 514/12; 435/183 435/320.1 435/325 435/69.1 530/350 536/23.2 A61K038/17 C07H021/04 C12N009/00 C12P021/02 C12N005/06 C07K014/435.
-
- ☐ 7. [20020076756](#). 11 May 01. 20 Jun 02. 28 human secreted proteins. Ruben, Steven M., et al. 435/69.1; 435/320.1 435/325 530/350 536/23.5 C12P021/02 C12N005/06 C07H021/04 C07K014/435.
-
- ☐ 8. [20020076705](#). 30 Mar 01. 20 Jun 02. 31 human secreted proteins. Ruben, Steven M., et al. 435/6; 435/320.1 435/325 435/69.1 536/23.2 C12Q001/68 C07H021/04 C12N005/06 C12P021/02.
-
- ☐ 9. [20020072102](#). 16 Mar 01. 13 Jun 02. Disintegrin homologs. Sheppard, Paul O., et al. 435/183; 435/320.1 435/325 435/69.1 C12P021/02 C12N005/06 C12N009/00.
-
- ☐ 10. [20020068319](#). 08 Mar 01. 06 Jun 02. 32 human secreted proteins. Ni, Jian, et al. 435/69.1; 435/183 435/325 435/7.1 530/388.1 536/23.5 C12P021/02 C12N005/06 G01N033/53 C07H021/04 C12N009/00.
-
- ☐ 11. [20020064818](#). 22 Feb 01. 30 May 02. 52 human secreted proteins. Ni, Jian, et al. 435/69.1; 435/325 435/6 435/7.1 536/23.1 C12P021/02 C12Q001/68 G01N033/53 C07H021/04 C12N005/06.
-
- ☐ 12. [20020061834](#). 09 Feb 01. 23 May 02. Human G-protein Chemokine receptor (CCR5) HDGNR10. Rosen, Craig A., et al. 514/1; 435/320.1 435/325 435/69.1 530/350 536/23.5 A61K031/00 C07H021/04 C07K014/705 C12N005/06 C12P021/02.
-
- ☐ 13. [20020061521](#). 17 Jan 01. 23 May 02. Nucleic acids, proteins, and antibodies. Rosen, Craig A., et al. 435/6; 435/69.1 514/2 530/300 536/23.1 C12Q001/68 C12P021/06 A01N037/18 C07H021/00

A61K038/00.

-
- ☐ 14. 20020048786. 09 Feb 01. 25 Apr 02. Human G-protein Chemokine Receptor HDGMR10. Rosen, Craig A., et al. 435/69.1; 424/130.1 435/325 435/7.2 514/12 536/23.5 G01N033/53 G01N033/567 A61K038/00 C07H021/04 C12P021/06 A61K039/395 C12N005/02 C12N005/00.
-
- ☐ 15. 20020028449. 01 Dec 00. 07 Mar 02. 26 Human secreted proteins. Ruben, Steven M., et al. 435/6; 435/183 435/69.1 530/388.1 536/23.1 C12Q001/68 C07H021/02 C07H021/04 C12P021/02 C12N009/00.
-
- ☐ 16. 20020026040. 16 Jul 01. 28 Feb 02. 49 human secreted proteins. Moore, Paul A., et al. 536/23.1; 435/6 530/300 C12Q001/68 C07H021/02 C07H021/04 C07K002/00 C07K004/00 C07K005/00 C07K007/00 C07K014/00 C07K016/00 C07K017/00 A61K038/00.
-
- ☐ 17. 20020025553. 01 Dec 00. 28 Feb 02. Transforming growth factor alpha HIII. Wei, Ying-Fei. 435/69.1; 435/325 435/7.1 530/399 536/23.5 C12P021/02 G01N033/53 C07H021/04 C12N005/06 C07K014/61.
-
- ☐ 18. 20020019349. 09 Feb 01. 14 Feb 02. Use of relaxin treat diseases related to vasoconstriction. Conrad, Kirk P., et al. 514/12; A61K038/00.
-
- ☐ 19. 20020012966. 25 Jan 01. 31 Jan 02. 18 Human secreted proteins. Shi, Yanggu, et al. 435/69.1; 435/183 435/325 530/350 536/23.1 C12P021/02 C07H021/04 C12N009/00 C12N005/08.
-
- ☐ 20. 20010021700. 19 Dec 00. 13 Sep 01. 49 human secreted proteins. Moore, Paul A., et al. 514/44; 435/320.1 435/325 435/69.1 435/69.7 435/7.1 514/12 530/350 530/388.2 536/23.5 A61K048/00 G01N033/53 A61K038/16 C07H021/04.
-

Generate Collection

Print

Terms	Documents
14 and infusi\$	30

[Previous Page](#)

[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 30 of 30 returned.**

-
- ☒ 21. [20010016193](#). 19 Dec 00. 23 Aug 01. Methods of altering cardiac cell phenotype. Engler, Robert L.. 424/93.21; 435/320.1 A61K048/00.
-
- ☐ 22. [6447771](#). 09 Aug 99; 10 Sep 02. Methods and materials relating to novel CD39-like polypeptides. Ford; John, et al. 424/94.61; A61K038/47.
-
- ☐ 23. [6433145](#). 20 Jan 00; 13 Aug 02. Keratinocyte derived interferon. LaFleur; David W., et al. 530/351; 424/85.4 435/7.1 530/350. C07K017/00 C07K014/00 A61K038/21 C12Q001/68.
-
- ☐ 24. [6391589](#). 07 Jan 00; 21 May 02. Human chemokine beta-10 mutant polypeptides. Olsen; Henrik S., et al. 435/69.5; 424/85.1 435/252.3 435/254.11 435/320.1 435/325 435/471 435/71.1 435/71.2 514/12 514/2 514/8 530/324 536/23.1 536/23.5. C12N005/10 C12N015/19 C12N015/63 C07K014/52 A61K038/19.
-
- ☐ 25. [6372473](#). 04 Oct 99; 16 Apr 02. Tissue plasminogen activator-like protease. Moore; Paul A., et al. 435/212; 435/217 530/327 530/328 530/350 530/827 530/828. C12N009/48 C12N009/68 C07K007/09 C07K007/08 C07K004/12.
-
- ☐ 26. [6335013](#). 30 Jun 00; 01 Jan 02. Methods and materials relating to CD39-like polypeptides. Ford; John, et al. 424/94.61; 514/12. A61K038/47.
-
- ☐ 27. [6265199](#). 09 Jul 99; 24 Jul 01. Disintegrin homologs. Sheppard; Paul O., et al. 435/212; 530/300 530/350. C12N009/48.
-
- ☐ 28. [6174871](#). 10 Aug 98; 16 Jan 01. Gene therapies for enhancing cardiac function. Hammond; H. Kirk, et al. 514/44; 424/93.6 435/320.1 536/23.5. A01N043/04 A01N063/00 A61K031/70 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
-
- ☐ 29. [6151525](#). 02 Sep 98; 21 Nov 00. Method and system for myocardial identifier repair. Soykan; Orhan, et al. 607/50; 607/3. A61N001/08.
-
- ☐ 30. [6140084](#). 01 Dec 98; 31 Oct 00. Human thyroid protein zsig45. Deisher; Theresa A., et al. 435/69.4; 435/252.3 435/320.1 435/325 435/360 435/69.1 536/23.1 536/23.5 536/23.51. C12P021/06 C12N015/00 C12N001/20 C07H021/04.
-

[Generate Collection](#)[Print](#)

Terms	Documents
14 and infusi\$	30

[Previous Page](#)[Next Page](#)